Kazakhstan vs Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD): Immunization, Hib3
Immunization, Hib3 over time
- Kazakhstan
- Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)
How they compare
Kazakhstan currently reports 98.0% against 83.7% in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD), a difference of 14.3%.
That makes Kazakhstan's figure about 1.2 times Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)'s.
Across all 17 years both countries report, Kazakhstan has been ahead every year.
Kazakhstan ranks 20th and Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) ranks 21st of 191 countries.
Kazakhstan has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Kazakhstan | Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 73.0% | 32.2% | 40.8% | Kazakhstan |
| 2010s | 95.6% | 67.9% | 27.7% | Kazakhstan |
| 2020s | 95.8% | 82.5% | 13.3% | Kazakhstan |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher immunization, hib3, Kazakhstan or Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- Kazakhstan, at 98.0% against 83.7% in Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) as of 2024.
- What is the difference in immunization, hib3 between Kazakhstan and Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- 14.3%, with Kazakhstan ahead.
- How many years of comparable data are there for Kazakhstan and Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD)?
- 17 years are reported by both, from 2008 to 2024.
- How do Kazakhstan and Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) rank globally for immunization, hib3?
- Kazakhstan ranks 20th and Middle East, North Africa, Afghanistan & Pakistan (IDA & IBRD) ranks 21st of 191 countries.
- Where does this data come from?
- WHO and UNICEF (http://www.who.int/immunization/monitoring_surveillance/en/), published as Immunization, Hib3 (% of children ages 12-23 months). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Child immunization, Hib3, measures the percentage of children ages 12-23 months who received Hib3 vaccinations before 12 months or at any time before the survey. A child is considered adequately immunized against Hib3 after receiving three doses of Haemophilus influenzae type b vaccine.